Uppsala, Sweden, May 14, 2020 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces that data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Annual meeting taking place between May 29 -June 02, 2020.

The poster, entitled; “Pharmacokinetics, safety and early activity of a nanoparticle micellar formulation of docetaxel in women with metastatic breast cancer: Results of two randomized trials (phase I and II)” will be presented by Dr Markus Joerger, MD, PhD, Cantonal Hospital, St. Gallen, Switzerland at the session Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. The phase I study was performed to determine the pharmacokinetics of docetaxel micellar in 30 patients and the phase II study was a randomized active-controlled study where 200 patients were treated. The bioequivalence of docetaxel micellar to docetaxel and the improved safety profile will be presented and discussed in relation to the future development program of the product.

“We are pleased to present and discuss this important research, which highlights results from our pipeline. Our clinical program continues to advance our XR-17 technology platform,” says Dr. Reinhard Koenig, Acting Chief Medical Officer at Oasmia Pharmaceutical.

ASCO is an organization for clinical oncologists and provides recommendations for clinical practices and publishes the scientific journal Journal of Clinical Oncology among other things. Due to public health safety concerns related to COVID-19, this year’s meeting will be a global virtual event held during the dates of the originally planned in-person Annual meeting.

For more information:

Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Michael af Winklerfelt, Chief Financial Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com

Consilium Strategic Communications
Jonathan Birt, Chris Welsh
Phone: +44 (0)20 3709 5700
E-mail: oasmia@conailium-comms.com

The information was submitted for publication, through the agency of the contact persons set out above, at 08.00am CET on May 14, 2020.

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR-17. Oasmia has been successful in driving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has applied for and achieved market approval in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea® and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories.